特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

喘息・COPD治療の世界市場 - 上位企業26社:2020年~2030年

Pharma Leader Series - Top 26 Asthma & COPD Companies 2020-2030: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

発行 Visiongain Ltd 商品コード 933203
出版日 ページ情報 英文 177 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=142.71円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

喘息・COPD治療の世界市場 - 上位企業26社:2020年~2030年 Pharma Leader Series - Top 26 Asthma & COPD Companies 2020-2030: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast
出版日: 2020年02月17日 ページ情報: 英文 177 Pages
概要

世界の喘息・COPD治療市場は、2018年に362億1000万米ドルで、2030年までに608億米ドルまで拡大すると予測されています。将来のビジネスチャンスを活用するために、市場における上位企業26社に関する詳細な考察を提供します。市場に影響を与える主な要因や課題も提供します。

当レポートでは、世界の喘息・COPD治療市場について調査分析し、上位企業26社を対象に、企業概要と分析、上市製品・製品パイプラインのポートフォリオ、財務情報、収益予測、最近の動向、将来の見通しについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 喘息・COPD治療のイントロダクション

  • COPDの概要
  • 喘息の概要
  • 喘息・COPD治療の呼吸器疾患用吸入器の概要
  • 喘息・COPD治療 - 成長可能性、市場促進要因
  • 市場抑制要因
  • 喘息・COPD製品:動向と開発

第3章 喘息・COPD治療の主要企業:概要

  • 世界の喘息・COPD治療企業
  • 喘息・COPD治療市場の主要企業
  • 主要企業の市場シェアの変化

第4章 世界の主要な喘息・COPD治療企業

  • Astrazeneca
  • Glaxosmithkline
  • Boehringer Ingelheim
  • Teva
  • Merck
  • Roche
  • Novartis
  • Regeneron Pharmaceuticals (Sanofi)
  • Mundipharma
  • Theravance Biopharma
  • Amphastar Pharmaceuticals
  • Cipla
  • Sunovion Pharmaceuticals
  • Aerocrine (Circassia)
  • Vectura Group
  • Lallemand Pharma Ag
  • Chiesi Farmaceutici S.P.A.
  • Pulmatrix
  • Verona Pharma Pl
  • Alk-Abello A/S
  • Tff Pharmaceuticals, Inc.
  • Respiratorius Ab
  • Adamis Pharmaceuticals Corporation
  • Dimerix
  • Innoviva
  • Mereo Biopharma Group Plc

第5章 結論

図表

List of tables

  • Table 2.1 Advantages and Disadvantages of The Main Types of Asthma Inhalers
  • Table 2.2 E-Technology Based Inhalers
  • Table 3.1 Global Market Forecast: Revenues ($Bn), AGR (%) By Leading Companies, 2019-2030
  • Table 3.2 Leading Companies in Asthma & COPD Diseases
  • Table 3.3 Leading Asthma & COPD Companies: Revenues ($Bn) And Market Shares (%), 2019 And 2030
  • Table 4.1 Astrazeneca: Company Overview
  • Table 4.2 Astrazeneca: Products Portfolio
  • Table 4.3 Astrazeneca: Products Pipeline Portfolio
  • Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.5 Glaxosmithkline: Company Overview
  • Table 4.6 Glaxosmithkline: Products Portfolio
  • Table 4.7 Glaxosmithkline: Products Pipeline Portfolio
  • Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.9 Boehringer Ingelheim: Company Overview
  • Table 4.10 Boehringer Ingelheim: Products Portfolio
  • Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.12 Teva: Company Overview
  • Table 4.13 Teva: Products Portfolio
  • Table 4.14 Teva: Products Pipeline Portfolio
  • Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($Bn), AGR(%), CAGR (%), 2019-2030
  • Table 4.16 Merck: Company Overview
  • Table 4.17 Merck: Products Portfolio
  • Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.19 Roche: Company Overview
  • Table 4.20 Roche: Products Portfolio
  • Table 4.21 Roche: Products Pipeline Portfolio
  • Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.23 Novartis: Company Overview
  • Table 4.24 Novartis: Products Portfolio
  • Table 4.25 Novartis: Products Pipeline Portfolio
  • Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview
  • Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
  • Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.30 Mundipharma: Company Overview
  • Table 4.31 Mundipharma: Products Portfolio
  • Table 4.32 Mundipharma: Products Pipeline Portfolio
  • Table 4.33 Theravance Biopharma: Company Overview
  • Table 4.34 Theravance Biopharma: Products Portfolio
  • Table 4.35 Theravance Biopharma: Products Pipeline Portfolio
  • Table 4.36 Amphastar Pharmaceuticals: Company Overview
  • Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio
  • Table 4.38 Cipla: Company Overview
  • Table 4.39 Cipla: Products Portfolio
  • Table 4.40 Sunovion Pharmaceuticals: Company Overview
  • Table 4.41 Sunovion Pharmaceuticals: Products Portfolio
  • Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.43 Circassia: Company Overview
  • Table 4.44 Circassia: Products Portfolio
  • Table 4.45 Circassia: Products Pipeline Portfolio
  • Table 4.46 Vectura Group: Company Overview
  • Table 4.47 Vectura Group: Products Portfolio
  • Table 4.48 Vectura Group: Products Pipeline Portfolio
  • Table 4.49 Lallemand Pharma Ag: Company Overview
  • Table 4.50 Lallemand Pharma Ag: Products Portfolio
  • Table 4.51 Lallemand Pharma Ag: Products Pipeline Portfolio
  • Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview
  • Table 4.53 Chiesi Farmaceutici S.P.A: Products Portfolio
  • Table 4.54 Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio
  • Table 4.55 Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), CAGR (%), 2019-2030
  • Table 4.56 Pulmatrix: Company Overview
  • Table 4.57 Pulmatrix: Products Pipeline Portfolio
  • Table 4.58 Verona Pharma Plc: Company Overview
  • Table 4.59 Verona Pharma Plc: Products Pipeline Portfolio
  • Table 4.60 Alk-Abelló A/S: Company Overview
  • Table 4.61 Alk-Abelló A/S Products Portfolio
  • Table 4.62 Alk-Abelló A/S: Products Pipeline Portfolio
  • Table 4.60 Tff Pharmaceuticals, Inc.: Company Overview
  • Table 4.62 Tff Pharmaceuticals, Inc.: Products Pipeline Portfolio
  • Table 4.60 Respiratorius Ab: Company Overview
  • Table 4.62 Respiratorius Ab: Products Pipeline Portfolio
  • Table 4.63 Respiratorius Ab: Resp1000 Patent Portfolio
  • Table 4.63 Respiratorius Ab: Resp2000 Patent Portfolio
  • Table 4.60 Adamis Pharmaceuticals Corporation: Company Overview
  • Table 4.62 Adamis Pharmaceuticals Corporation: Products Pipeline Portfolio
  • Table 4.60 Dimerix: Company Overview
  • Table 4.62 Dimerix: Products Pipeline Portfolio
  • Table 4.60 Innoviva: Company Overview
  • Table 4.61 Innoviva Products Portfolio
  • Table 4.60 Mereo Biopharma Group Plc: Company Overview
  • Table 4.62 Mereo Biopharma Group Plc: Products Pipeline Portfolio

List of Figures

  • Figure 1.1 Global Asthma & COPD Companies Market Segmentation Overview, 2020-2030
  • Figure 2.1 Stepwise Approach to Treatment Of COPD
  • Figure 2.2 Stepwise Approach to Treatment Of Asthma
  • Figure 3.1 Global: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 3.2 Leading Asthma & COPD Drug Manufacturers: Revenue ($Bn), 2019
  • Figure 3.3 Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019
  • Figure 3.4 Leading Asthma & COPD Companies: Revenues ($Bn), 2030
  • Figure 3.5 Leading Asthma & COPD Companies: Market Shares (%), 2030
  • Figure 4.1 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.2 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.3 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.4 Teva: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.5 Merck: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.6 Roche: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.7 Novartis: Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.8 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.9 Sunovion Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 4.10 Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($Bn), AGR (%), 2019-2030
  • Figure 5.1 World Asthma & COPD Products Market Forecast: Revenues ($Bn), 2019-2030

List of Companies and Organizations Mentioned in the Report:

  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • American College of Chest Physicians (ACCP)
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Ciba-Geigy
  • Cipla
  • Committee for Medicinal Products for Human Use (CHMP)
  • Dainippon Sumitomo Pharma America, Inc.
  • Dermira Inc.
  • European Medicines Agency (EMA)
  • European Respiratory Society (ERS)
  • GlaxoSmithKline (GSK)
  • Glenmark
  • Hikma
  • Innovata plc
  • Innoviva, Inc.
  • Japanese Ministry of Health, Labour and Welfare
  • Lallemand Pharma International
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Merck
  • Monitored Therapeutics, Inc. (MTI)
  • MundiPharma
  • Mylan
  • National Institute for Health and Care Excellence (NICE)
  • Novartis
  • Pulmatrix
  • Regeneron
  • Roche
  • Sandoz
  • Sanofi
  • Sepracor Inc.
  • Sorrento
  • Sunovion
  • Teva
  • Theravance Biopharma-Mylan Inc.
  • Torii
  • Vectura Group plc
  • Verona Pharma plc
目次
Product Code: PHA0713

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 177-page report you will receive 100 charts - all unavailable elsewhere.

The 177-page report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Asthma & COPD Therapies Market forecasts from 2020-2030

Profiles of the leading 26 asthma & COPD companies :

  • Adamis Pharmaceuticals Corporation
  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • Dimerix
  • GlaxoSmithKline
  • Innoviva
  • Lallemand Pharma International
  • Merck
  • Mereo BioPharma Group plc
  • MundiPharma
  • Novartis
  • Pulmatrix
  • Respiratorius AB
  • Roche
  • Other companies

The content of each profile differs, depending on the organization. In general, a profile gives the following information:

  • An overview and analysis of the company
  • A portfolio of the company's marketed product and product pipeline
  • Financial Information
  • Revenue forecast from 2020-2030
  • Recent developments
  • Future Outlook

This report discusses factors that drive and restrain the asthma and COPD market.

Key questions answered by this report:

  • How is the Asthma & COPD Companies market evolving?
  • What is driving and restraining the Asthma & COPD Companies market?
  • What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
  • What will be the main driver for the overall market from 2019 to 2030?
  • Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
  • How will the industry evolve during the period between 2019 and 2030?

Visiongain's study is intended for anyone requiring commercial analyses for the top 26 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030 : Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast .

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1 Report Overview

  • 1.1 Global Asthma & COPD Companies Market Overview
  • 1.2 Global Asthma & COPD Companies Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Introduction to Asthma & COPD Therapies

  • 2.1 COPD Overview
    • 2.1.1 Chronic Obstructive Pulmonary Disease Medications
      • 2.1.1.1 Bronchodilators
      • 2.1.1.2 Glucocorticoids
  • 2.2 Asthma Overview
    • 2.2.1 Desirable inhaler characteristics for treating asthma
  • 2.3 Asthma & COPD Respiratory Inhalers Overview
    • 2.3.1 Nebulizers
    • 2.3.2 Metered Dose Inhaler
    • 2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers
    • 2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
    • 2.3.5 Dry powder inhalers (DPIs)
    • 2.3.6 Soft Mist Inhalers
  • 2.4 Asthma & COPD Therapies - Realising Their Potential, Market Drivers
    • 2.4.1 Combination Therapies - Asthma & COPD Products
      • 2.4.1.1 LAMA/LABA Combinations
      • 2.4.1.2 LABA/LCS Combination
      • 2.4.1.3 LABA+LAMA Vs. LABA+ICS Combinations
    • 2.4.2 Triple Combination - Asthma & COPD Products
      • 2.4.2.1.1 LAMA/LABA/ICS “Triple Combination Inhalers”
    • 2.4.3 Opportunities in Telehealth
  • 2.5 Market Restraints
  • 2.6 Asthma & COPD Products: Trends and Developments
    • 2.6.1 E-Technology in Asthma and COPD

3 Leading Asthma & COPD Companies: Overview, 2019

  • 3.1 The Global Asthma & COPD Companies Market In 2019
  • 3.2 Leading Companies in the Asthma & COPD Market, 2020
  • 3.3 How Will Leading Companies' Market Shares Change To 2030?

4 Leading Asthma & COPD Companies Worldwide, 2020

  • 4.1 Astrazeneca - Company Overview & Analysis
    • 4.1.1 Astrazeneca Marketed Asthma & COPD Products
      • 4.1.1.1 Latest Developments Related to Key Marketed Products
        • 4.1.1.1.1 Symbicort: Recent Developments
        • 4.1.1.1.2 Bevespi Aerosphere: Recent Developments
        • 4.1.1.1.3 Tudorza/ Eklira Genuair: Recent Developments
        • 4.1.1.1.4 Duaklir: Recent Developments
        • 4.1.1.1.5 Fasenra: Recent Developments
        • 4.1.1.1.6 Other Recent Developments
    • 4.1.2 Astrazeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.1.2.1 Latest Developments Related to Key Pipeline Products
        • 4.1.2.1.1 Pt010/ Pt009/ Pt008/ Pt005: Pipeline Developments
        • 4.1.2.1.2 Fasenra: Pipeline Developments
        • 4.1.2.1.3 Tezepelumab: Pipeline Developments
        • 4.1.2.1.4 Tralokinumab: Pipeline Developments
    • 4.1.3 Astrazeneca -Asthma & COPD Market Forecast, 2019-2030
  • 4.2 Glaxosmithkline - Company Overview & Analysis
    • 4.2.1 Glaxosmithkline Marketed Asthma & COPD Products
      • 4.2.1.1 Latest Developments Related to Key Marketed Products
        • 4.2.1.1.1 Relvar/Breo Ellipta: Recent Developments
        • 4.2.1.1.2 Anoro Ellipta: Recent Developments
        • 4.2.1.1.3 Nucala: Recent Developments
        • 4.2.1.1.4 Seretide/Advair: Recent Developments
        • 4.2.1.1.5 Trelegy Ellipta: Recent Developments
        • 4.2.1.1.6 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments
    • 4.2.2 Glaxosmithkline, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.2.2.1 Latest Developments Related to Key Pipeline Products
        • 4.2.2.1.1 Nucala: Recent Developments
    • 4.2.3 Glaxosmithkline -Asthma & COPD Market Forecast, 2019-2030
  • 4.3 Boehringer Ingelheim - Company Overview & Analysis
    • 4.3.1 Boehringer Ingelheim Marketed Asthma & COPD Products
      • 4.3.1.1 Latest Developments Related to Key Marketed Products
        • 4.3.1.1.1 Spiriva Respimat: Recent Developments
        • 4.3.1.1.1 Spiolto Respimat: Recent Developments
        • 4.3.1.1.2 Ofev: Recent Developments
    • 4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2019-2030
  • 4.4 Teva - Company Overview & Analysis
    • 4.4.1 Teva Marketed Asthma & COPD Products
      • 4.4.1.1 Latest Developments Related to Key Marketed Products
        • 4.4.1.1.1 Qvar: Recent Developments
        • 4.4.1.1.2 Proair HFA: Recent Development
        • 4.4.1.1.3 : Duoresp Spiromax: Recent Developments
        • 4.4.1.1.4 Aerivio Spiromax: Recent Developments
        • 4.4.1.1.5 Cinqair/Cinqaero: Recent Developments
        • 4.4.1.1.6 Airduo Respiclick / Armonair Respiclick: Recent Development
    • 4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.4.2.1 Latest Developments Related to Key Pipeline Products
        • 4.4.2.1.1 Proair E-Respiclick: Recent Developments
    • 4.4.3 Teva -Asthma & COPD Market Forecast, 2019-2030
  • 4.5 Merck - Company Overview & Analysis
    • 4.5.1 Merck Marketed Asthma & COPD Products
      • 4.5.1.1 Latest Developments Related to Key Marketed Products
        • 4.5.1.1.1 Dulera: Recent Development
    • 4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.5.3 Merck -Asthma & COPD Market Forecast, 2019-2030
  • 4.6 Roche - Company Overview & Analysis
    • 4.6.1 Roche Marketed Asthma & COPD Products
      • 4.6.1.1 Latest Developments Related to Key Marketed Products
        • 4.6.1.1.1 Xolair: Recent Developments
    • 4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.6.2.1 Latest Developments Related to Key Pipeline Products
        • 4.6.2.1.1 Rg3637: Pipeline Developments
    • 4.6.3 Roche -Asthma & COPD Market Forecast, 2019-2030
  • 4.7 Novartis - Company Overview & Analysis
    • 4.7.1 Novartis Marketed Asthma & COPD Products
      • 4.7.1.1 Latest Developments Related to Key Marketed Products
        • 4.7.1.1.1 Ultibro Breezhaler: Recent Developments
        • 4.7.1.1.2 Xolair: Recent Developments
    • 4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.7.2.1 Latest Developments Related to Key Pipeline Products
        • 4.7.2.1.1 Qaw039: Pipeline Developments
        • 4.7.2.1.2 Qbw251: Pipeline Developments
        • 4.7.2.1.3 Qvm149: Pipeline Developments
        • 4.7.2.1.4 Csj117: Pipeline Developments
        • 4.7.2.1.5 Cjm112: Pipeline Developments
    • 4.7.3 Novartis -Asthma & COPD Market Forecast, 2019-2030
  • 4.8 Regeneron Pharmaceuticals (Sanofi)- Company Overview & Analysis
    • 4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.8.1.1 Latest Developments Related to Key Pipeline Products
        • 4.8.1.1.1 Dupilimab/ Dupixent/Sar23189: Pipeline Developments
        • 4.8.1.1.2 Sar440340: Pipeline Developments
    • 4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2019-2030
  • 4.9 Mundipharma - Company Overview & Analysis
    • 4.9.1 Mundipharma Marketed Asthma & COPD Products
      • 4.9.1.1 Latest Developments Related to Key Marketed Products
        • 4.9.1.1.1 Flutiform (Fluticasone Propionate and Formoterol): Recent Developments
        • 4.9.1.1.2 Company Related Developments
    • 4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.9.2.1 Latest Developments Related to Key Pipeline Products
        • 4.9.2.1.1 Flutiform K-Haler (Fluticasone Propionate and Formoterol): Recent Developments
  • 4.10 Theravance Biopharma - Company Overview & Analysis
    • 4.10.1 Theravance Biopharma Marketed Asthma & COPD Products
      • 4.10.1.1 Latest Developments Related to Key Marketed Products
        • 4.10.1.1.1 Trelegy Ellipta: Recent Developments
    • 4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.10.2.1 Latest Developments Related to Key Pipeline Products
        • 4.10.2.1.1 Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA): Recent Developments
        • 4.10.2.2 Revefenacin (Td-4208): Recent Developments
  • 4.11 Amphastar Pharmaceuticals - Company Overview & Analysis
    • 4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.11.1.1 Latest Developments Related to Key Pipeline Products
        • 4.11.1.1.1 Primatene Mist HFA: Recent Developments
        • 4.11.1.1.2 Albuterol Dpi: Recent Developments
  • 4.12 Cipla- Company Overview & Analysis
    • 4.12.1 Cipla Marketed Asthma & COPD Products
      • 4.12.1.1 Latest Developments Related to Key Marketed Products
        • 4.12.1.1.1 Budesonide Inhalation Suspension: Pipeline Developments
        • 4.12.1.1.2 Synchrobreathe: Pipeline Developments
      • 4.12.1.2 Cipla Launch Plans for Respiratory Products
  • 4.13 Sunovion Pharmaceuticals- Company Overview & Analysis
    • 4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD Products
      • 4.13.1.1 Latest Developments Related to Key Marketed Products
        • 4.13.1.1.1 Sun-101: Recent Developments
    • 4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.13.3 Sunovion -Asthma & COPD Market Forecast, 2019-2030
  • 4.14 Aerocrine (Circassia)- Company Overview & Analysis
    • 4.14.1 Circassia Marketed Asthma & COPD Products
      • 4.14.1.1 Latest Developments Related to Key Marketed Products
        • 4.14.1.1.1 Niox: Recent Developments
        • 4.14.1.1.2 Tudorza Pressair: Recent Developments
    • 4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.14.2.1 Latest Developments Related to Key Pipeline Products
        • 4.14.2.1.1 Duaklir Pressair Us: Pipeline Developments
    • 4.14.3 Circassia -Asthma & COPD Market Forecast, 2019-2030
  • 4.15 Vectura Group - Company Overview & Analysis
    • 4.15.1 Vectura Group Marketed Asthma & COPD Products
      • 4.15.1.1 Latest Developments Related to The Marketed Products
        • 4.15.1.1.1 Flutiform (Mundipharma, Europe And Rest of World (Excl. North America)/Kyorin, Japan): Recent Developments
        • 4.15.1.1.2 Ultibro Breezhaler, Seebri Breezhaler Utibron Neohaler Inhalation Powder and Seebri Neohaler (Novartis/Sunovion, US): Recent Developments
        • 4.15.1.1.3 GSK Ellipta Products: Recent Developments
        • 4.15.1.1.4 Airflusal Forspiro (Sandoz, Eu & Row): Recent Developments
        • 4.15.1.1.5 Breelibtm (Bayer, Eu & Row Excluding Us): Recent Developments
    • 4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.15.2.1 Latest Developments Related to The Pipeline Products
        • 4.15.2.1.1 Vr647 (Paediatric Asthma Us): Recent Developments
        • 4.15.2.1.2 Vr475 (Severe Adult Asthma Eu): Recent Developments
        • 4.15.2.1.3 Vr315 (Hikma, Us): Recent Developments
        • 4.15.2.1.4 Vr632 (Sandoz, Eu): Recent Developments
        • 4.15.2.1.5 Vr410 (Pulmatrix, Us): Recent Developments
        • 4.15.2.1.6 Qvm149 (Novartis: Europe & Row): Recent Developments
        • 4.15.2.1.7 Key Outlook For 2018-2019
    • 4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2019-2030
  • 4.16 Lallemand Pharma Ag- Company Overview & Analysis
    • 4.16.1 Lallemand Pharma Ag Marketed Asthma & COPD Products
      • 4.16.1.1 Latest Development Related to The Marketed Products
        • 4.16.1.1.1 PMBL: Recent Developments
    • 4.16.2 Lallemand Pharma Ag, Asthma & COPD Products- R&D Pipeline & Future Outlook
    • 4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2019-2030
  • 4.17 Chiesi Farmaceutici S.P.A. - Company Overview & Analysis
    • 4.17.1 Chiesi Farmaceutici S.P.A Marketed Asthma & COPD Products
      • 4.17.1.1 Latest Developments Related to Key Marketed Products
        • 4.17.1.1.1 Trimbow: Recent Developments
    • 4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.17.2.1 Latest Developments Related to Key Pipeline Products
        • 4.17.2.1.1 Bronchitol: Recent Development
        • 4.17.2.1.2 CHF 6297: Recent Development
    • 4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2019-2030
  • 4.18 Pulmatrix: Company Overview & Analysis
    • 4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.18.1.1 Latest Developments Related to Key Pipeline Products
        • 4.18.1.1.1 Pur0200-Us: Recent Development
        • 4.18.1.1.2 Pur1900: Recent Development
  • 4.19 Verona Pharma Plc- Company Overview & Analysis
    • 4.19.1 Verona Pharma Plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.19.1.1 Latest Development Related to The Pipeline Products
        • 4.19.1.1.1 Rpl554: Recent Developments
    • 4.19.2 Verona Pharma Plc -Asthma & COPD Market Forecast, 2019-2030
  • 4.20 Alk-Abelló A/S- Company Overview & Analysis
    • 4.20.1 Alk-Abelló A/S Marketed Asthma & COPD Products
    • 4.20.2 Alk-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.20.2.1 Latest Developments Related to The Pipeline Products
        • 4.20.2.1.1 Grazax: Recent Developments
    • 4.20.3 Alk-Abelló A/S -Asthma & COPD Market Forecast, 2019-2030
  • 4.21 Tff Pharmaceuticals, Inc.- Company Overview & Analysis
    • 4.21.1 Tff Pharmaceuticals, Inc. Marketed Asthma & COPD Products
    • 4.21.2 Tff Pharmaceuticals, Inc.: Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.21.2.1 Latest Developments Related to The Pipeline Products
        • 4.21.2.1.1 Tff Triple Combination: Recent Developments
    • 4.21.3 Tff Pharmaceuticals, Inc.-Asthma & COPD Market Forecast, 2019-2030
  • 4.22 Respiratorius Ab - Company Overview & Analysis
    • 4.22.1 Respiratorius Ab. Marketed Asthma & COPD Products
    • 4.22.2 Respiratorius Ab: Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.22.2.1 Latest Developments Related to The Pipeline Products
        • 4.22.2.1.1 Product: Recent Developments
    • 4.22.3 Respiratorius Ab-Asthma & COPD Market Forecast, 2019-2030
  • 4.23 Adamis Pharmaceuticals Corporation- Company Overview & Analysis
    • 4.23.1 Adamis Pharmaceuticals Corporation. Marketed Asthma & COPD Products
    • 4.23.2 Adamis Pharmaceuticals Corporation: Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.23.2.1 Latest Developments Related to the Pipeline Products
        • 4.23.2.1.1 Product: Recent Developments
    • 4.23.3 Adamis Pharmaceuticals Corporation. -Asthma & COPD Market Forecast, 2019-2030
  • 4.24 Dimerix - Company Overview & Analysis
    • 4.24.1 Dimerix Marketed Asthma & COPD Products
    • 4.24.2 Dimerix: Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.24.2.1 Latest Developments Related to The Pipeline Products
        • 4.24.2.1.1 Product: Recent Developments
    • 4.24.3 Dimerix -Asthma & COPD Market Forecast, 2019-2030
  • 4.25 Innoviva- Company Overview & Analysis
    • 4.25.1 Innoviva. Marketed Asthma & COPD Products
      • 4.25.1.1 Product: Recent Developments
    • 4.25.2 Innoviva. -Asthma & COPD Market Forecast, 2019-2030
  • 4.26 Mereo Biopharma Group Plc- Company Overview & Analysis
    • 4.26.1 Mereo Biopharma Group Plc Marketed Asthma & COPD Products
    • 4.26.2 Mereo Biopharma Group Plc: Asthma & COPD Products- R&D Pipeline & Future Outlook
      • 4.26.2.1 Latest Developments Related to the Pipeline Products
        • 4.26.2.1.1 Product: Recent Developments
    • 4.26.3 Mereo Biopharma Group Plc -Asthma & COPD Market Forecast, 2019-2030

5 Conclusions

  • 5.1 Asthma & COPD Products: A Maturing Market
  • 5.2 The Global Asthma & COPD Companies Market In 2020-2030
  • 5.3 Leading Asthma & COPD Companies
  • 5.4 Global Asthma & COPD Products Market Forecast 2020-2030
  • 5.5 The Future of the Asthma & COPD Products Market
    • 5.5.1 Growth in Anti-Inflammatory and Combination Drugs
    • 5.5.2 Personalised Medicine
    • 5.5.3 Unmet needs in Asthma and COPD
  • 5.6 Strategies for Growth in 2020-2030
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form